|
"Delivery of therapeutic proteins as secretable TAT fusion products", MOL THER., vol. 17, no. 2, February 2009 (2009-02-01), pages 334 - 42
|
|
"GenBank", Database accession no. NC_001510.1
|
|
A. C. NATHWANI ET AL.: "Long-term safety and efficacy of factor IX gene therapy in hemophilia B", N ENGL J MED, vol. 371, 2014, pages 1994 - 2004, XP055241941, DOI: 10.1056/NEJMoa1407309
|
|
A. DONSANTE ET AL.: "AAV vector integration sites in mouse hepatocellular carcinoma", SCIENCE, vol. 317, 2007, pages 477
|
|
B. E. DEVERMAN ET AL.: "Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain", NAT BIOTECHNOL, vol. 34, 2016, pages 204 - 209, XP055328659, DOI: 10.1038/nbt.3440
|
|
C. FUCHS ET AL.: "Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder", NEURAL PLASTICITY, vol. 2018, 2018, pages 9726950
|
|
C. S. MANNO ET AL.: "Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response", NAT MED, vol. 12, 2006, pages 342 - 347, XP002578131
|
|
E. AMENDOLA ET AL.: "Mapping pathological phenotypes in a mouse model of CDKL5 disorder", PLOS ONE, vol. 9, 2014, pages e91613
|
|
ELLIGER S S ET AL: "Enhanced Secretion and Uptake of beta-Glucuronidase Improves Adeno-associated Viral-Mediated Gene Therapy of Mucopolysaccharidosis Type VII Mice", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, CELL PRESS, US, vol. 5, no. 5, 1 May 2002 (2002-05-01), pages 617 - 626, XP008090917, ISSN: 1525-0016
*
|
|
G. GAO ET AL.: "Clades of Adeno-associated viruses are widely disseminated in human tissues", J VIROL, vol. 78, 2004, pages 6381 - 6388, XP002321999, DOI: 10.1128/JVI.78.12.6381-6388.2004
|
|
GRAY ET AL., HUM GENE THER., vol. 22, no. 9, September 2011 (2011-09-01), pages 1143 - 115
|
|
GRAY ET AL., HUMAN GENE THERAPY, vol. 22, pages 1143 - 1153
|
|
GRIEGER ET AL.: "Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly", J VIROL., vol. 80, 2006, pages 5199 - 210, XP055386050, DOI: 10.1128/JVI.02723-05
|
|
GRIMM DZHOU SNAKAI HTHOMAS CESTORM TAFUESS SMATSUSHITA TALLEN JSUROSKY RLOCHRIE M: "Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy", BLOOD, vol. 102, 2003, pages 2412 - 2419
|
|
HUDRY ELOISE ET AL: "Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality", NEURON, vol. 101, no. 5, 6 March 2019 (2019-03-06), pages 839 - 862, XP085620117, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2019.02.017
*
|
|
J. M. POWERSX. L. CHANGZ. SONGH. NAKAI: "A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno- associated Virus Assembly-activating Proteins", J VIS EXP, 2018
|
|
MATSUSHITA TELLIGER SELLIGER CPODSAKOFF GVILLARREAL LKURTZMAN GJIWAKI YCOLOSI P: "Adeno-associated virus vectors can be efficiently produced without helper virus", GENE THER, vol. 5, 1998, pages 938 - 945, XP002098259, DOI: 10.1038/sj.gt.3300680
|
|
N. BAHI-BUISSONT. BIENVENU: "CDKL5-Related Disorders: From Clinical Description to Molecular Genetics", MOLECULAR SYNDROMOLOGY, vol. 2, 2012, pages 137 - 152
|
|
O. H. LOWRYN. J. ROSEBROUGHA. L. FARRR. J. RANDALL: "Protein measurement with the Folin phenol reagent", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 193, 1951, pages 265 - 275, XP000196391
|
|
POWERS JMCHANG XLSONG ZNAKAI H: "A Quantitative Dot Blot Assay for AAV Titration and Its Use for Functional Assessment of the Adeno-associated Virus Assembly-activating Proteins", J VIS EXP, 2018, pages 12
|
|
S. BASTIANINI ET AL.: "Accurate discrimination of the wake-sleep states of mice using non-invasive whole-body plethysmography", SCIENTIFIC REPORTS, vol. 7, 2017, pages 41698
|
|
S. J. GRAY ET AL.: "Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors", HUM GENE THER, vol. 22, 2011, pages 1143 - 1153, XP055198141, DOI: 10.1089/hum.2010.245
|
|
STEFANIA TRAZZI ET AL: "CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder", HUMAN MOLECULAR GENETICS, vol. 27, no. 9, 20 February 2018 (2018-02-20), pages 1572 - 1592, XP055653212, ISSN: 0964-6906, DOI: 10.1093/hmg/ddy064
*
|
|
STEFANIA TRAZZI ET AL: "CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.", HUMAN MOLECULAR GENETICS, 20 February 2018 (2018-02-20), pages 1 - 12, XP055653227, Retrieved from the Internet <URL:https://academic.oup.com/hmg/article/27/9/1572/4892297#supplementary-data> [retrieved on 20191216]
*
|
|
STEVEN J. GRAY ET AL: "Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors", HUMAN GENE THERAPY, vol. 22, no. 9, 1 September 2011 (2011-09-01), pages 1143 - 1153, XP055198141, ISSN: 1043-0342, DOI: 10.1089/hum.2010.245
*
|
|
V. LO MARTIRE ET AL.: "CDKL5 deficiency entails sleep apnoea's in mice", JOURNAL OF SLEEP RESEARCH, vol. 26, 2017, pages 495 - 497
|
|
XIAN-CANG MA ET AL: "Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder", SCIENTIFIC REPORTS, vol. 6, no. 1, 3 March 2016 (2016-03-03), XP055653418, DOI: 10.1038/srep22404
*
|